Atypical femoral fractures: retrospective radiological study of 319 femoral fractures and presentation of clinical cases

Bottai, Vanna; Giannotti, Stefano; Dell’Osso, G; Paola, Gaia De; Menconi, Agnese; Falossi, F.; Raffaeta, Gloria; Guido, Giulio

doi:10.1007/s00198-013-2546-8

Cited by 21 publications

(23 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The estimated incidence in patients given oral BPs at doses used for osteoporosis is lower at less than 1 in 100,000 patient treatment years [18]. In contrast, the incidence of AFF is not established [21]. A dose-response relationship has not been documented but the risk appears related to duration of treatment.…”

Section: Introductionmentioning

confidence: 97%

The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells

et al. 2015

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 97%

The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells

et al. 2015

View full text Add to dashboard Cite

“…Lenart et al (2) described as "atypical" fractures that involved the strongest part of the femur, the subtrochanteric and diaphyseal region, and then the American Society for Bone and Mineral Research Task force (3) identified major and minor features that define distinctly "typical" osteoporotic femoral fractures from "atypical" fractures. A recent review demonstrated that the incidence of atypical femoral fractures (AFFs) is 0.6%, according to data from the most recent literature, referred to all femoral fractures, including both medial fractures, lateral and diaphyseal fractures (4). Moreover, in the literature are reported atypical fractures that occur to other skeletal districts in addition to femur (1) and several case reports in the literature related periprosthetic femoral fractures to the same or similar pathology as that of an atypical femoral fracture (5,6).…”

Section: Introductionmentioning

confidence: 99%

Atypical periprosthetic acetabular fracture in long-term alendronate therapy

Marongiu

Capone

2016

ccmbm

View full text Add to dashboard Cite

SummaryBisphosphonates have been commonly used in the treatment of osteoporosis, demonstrating its efficacy in fracture risk reduction. However, even if are generally safe and well tolerated, concerns have emerged about atypical fractures related to its prolonged use. Although atypical femoral fracture are more common, case reports demonstrated that even other skeletal areas can be involved by unusual pattern of fracture. We report a atypical acetabular periprosthetic fracture in a 83-year-old female patient after prolonged alendronate treatment for osteoporosis and isolated acetabular revision surgery. The patient underwent to clinical, bioumoral and radiological evaluation and all the history cases were fully reported. We believe this periprosthetic fracture, according to the available data, may have similar underlying pathology to atypical femoral fractures. Awareness of symptoms, in addition to a regular radiographic survey may facilitate early diagnosis and possible prevention of spontaneous periprosthetic fractures, in patients receiving bisphosphonate therapy beyond 5 years. The treatment of this atypical periprosthetic fracture should include both surgical than pharmacological therapy to obtained bone healing.

show abstract

“…Moreover, some studies have suggested that bisphosphonates may prevent or may be used to treat aseptic loosening (23), or to prevent the decrease in proximal femoral BMD usually seen after hip replacement (24,25). Patients with THA and risk factors for loosening should be screened for osteoporosis and have regular radiological surveillance (3), especially if treated with BF for monitoring of any atypical periprosthesis fractures, in particular in areas neighboring the end of the prosthesis stem (26,27). Bone quality of the hip joint has become an important risk factor limiting the durability of THA (28).…”

Section: Discussionmentioning

confidence: 99%

Total hip replacement in osteoarthritis: the role of bone metabolism and its complications

Bottai

Dell’Osso

Celli

et al. 2015

ccmbm

View full text Add to dashboard Cite

SummaryOsteoarthritis is one of the most common joint disorder. For treatment of hip symptomatic osteoarthritis, when conservative medical therapy has failed, total hip arthroplasty (THA) is a successful orthopaedic procedures that reduces pain and improves function and quality of life. Incidence of osteoarthritis is constantly increasing with raising life expectancy. This aging process also has led to an increasing number of patients with osteoporosis who need hip replacement for osteoarthritis. Osteoporosis have 3 major potential complications in total hip arthroplasty: perioperative fracture, an increased risk of periprosthetic fracture, and late aseptic loosening. The purpose of the present study was to examine the effects of osteoporosis on total hip replacement procedure outcome and highlight the importance of adequate study of calcium-phosphorus metabolism in patient candidate for hip surgery, and the need to start a suitable therapy to recover the bone mass before surgery. Bone quality of the hip joint has become an important risk factor limiting the durability of THA.KEY WORDS: total hip replacement; bone metabolism; perioperative and periprosthetic fracture.

show abstract

Atypical femoral fractures: retrospective radiological study of 319 femoral fractures and presentation of clinical cases

Cited by 21 publications

References 13 publications

The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells

The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells

Atypical periprosthetic acetabular fracture in long-term alendronate therapy

Total hip replacement in osteoarthritis: the role of bone metabolism and its complications

Contact Info

Product

Resources

About